estradiol + progesterone + triptorelin

This refers to a hormone replacement therapy (HRT) protocol used in frozen embryo transfer (FET) cycles for infertility treatment, investigated in a Phase 4 randomized controlled trial led by Peter Humaidan. The protocol involves the administration of estradiol for endometrial preparation and vaginal progesterone for luteal phase support, supplemented with two bolus injections of the GnRH agonist triptorelin (0.1 mg). The triptorelin boluses are administered two days before the start of vaginal progesterone and on the seventh day of progesterone treatment. This regimen is designed to reduce early pregnancy loss and improve ongoing pregnancy rates in substituted FET cycles by optimizing the hormonal environment for embryo implantation and early development. It is not a single commercial product but a specific combination treatment regimen using existing pharmaceutical agents.

Other names

Substituted Frozen Embryo Transfer Cycles With GnRH-agonist SupplementationGnRH Agonist Supplementation in FET